Fwd: NGC Update Service: July 7, 2014

---------- Forwarded message ----------
From: Agency for Healthcare Research and Quality (AHRQ) <updates@subscriptions.ahrq.gov>
Date: Mon, Jul 7, 2014 at 9:01 AM
Subject: NGC Update Service: July 7, 2014
To: iammejtm@gmail.com

July 7, 2014 New This Week Guideline Summaries CancerControl Alberta Ovarian germ cell tumours. This updates a previously published guideline summary. Preoperative and pretreatment investigations for malignant melanoma. This updates a previously published guideline summary. Prostate cancer. This updates a previously published guideline summary. Referral and follow-up surveillance of cutaneous melanoma. This updates a previously published guideline summary. Squamous cell carcinoma of the vulva. This updates a previously published guideline summary. National Institute for Health and Care Excellence (NICE) Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion. Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma. Teriflunomide for treating relapsing–remitting multiple sclerosis. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44). This updates a previously published guideline summary. National Society of Genetic Counselors Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. This updates a previously published guideline summary. Announcements NGC Spotlight New evidence report added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program. Conference News The Guidelines International Network (G-I-N) Conference 2014, will be held August 20-23 in Melbourne, Australia. This year's theme is "Creation and Innovation: Guidelines in the Digital Age." Register now. The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisories June 25, 2014: Over-The-Counter Topical Acne Products: FDA is warning that certain over-the-counter (OTC) topical acne products can cause rare but serious and potentially life-threatening allergic reactions or severe irritation. Consumers should stop using their topical acne product and seek emergency medical attention immediately if they experience hypersensitivity reactions such as throat tightness; difficulty breathing; feeling faint; or swelling of the eyes, face, lips, or tongue. Consumers should also stop using the product if they develop hives or itching. The hypersensitivity reactions may occur within minutes to a day or longer after product use. These serious reactions differ from the local skin irritation that may occur at the product application site that are already included in the Drug Facts labels. June 24, 2014: Olmesartan: FDA has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication olmesartan in diabetic patients. FDA believes the benefits of olmesartan in patients with high blood pressure continue to outweigh the potential risks. Patients should not stop taking olmesartan or any blood pressure medication without first discussing it with their health care professional. Recommendations for use of olmesartan remain the same, but FDA will require information about some of the studies to be included in the drug labels. NGC's Sister Resources Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site. Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).    How satisfied are you with this e-mail bulletin? Give Us Your Feedback Subscriber Services: Change Your Profile | Unsubscribe | Help Stay Connected: Contact Us | Social Media This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364

--
Jeremy Tobias Matthews